AU2021437358A1 - Nasal compositions comprising alcaftadine - Google Patents

Nasal compositions comprising alcaftadine Download PDF

Info

Publication number
AU2021437358A1
AU2021437358A1 AU2021437358A AU2021437358A AU2021437358A1 AU 2021437358 A1 AU2021437358 A1 AU 2021437358A1 AU 2021437358 A AU2021437358 A AU 2021437358A AU 2021437358 A AU2021437358 A AU 2021437358A AU 2021437358 A1 AU2021437358 A1 AU 2021437358A1
Authority
AU
Australia
Prior art keywords
composition
nasal
alcaftadine
pharmaceutical composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021437358A
Other languages
English (en)
Inventor
Amol AIWALE
Babasaheb Aware
Viraj SHAH
Akhilesh Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkem Laboratories Ltd
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of AU2021437358A1 publication Critical patent/AU2021437358A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021437358A 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine Pending AU2021437358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (1)

Publication Number Publication Date
AU2021437358A1 true AU2021437358A1 (en) 2023-09-14

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021437358A Pending AU2021437358A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Country Status (12)

Country Link
US (6) US20240173331A1 (enExample)
EP (1) EP4312973A1 (enExample)
JP (1) JP2024512121A (enExample)
KR (1) KR20230163413A (enExample)
CN (1) CN117120029A (enExample)
AU (1) AU2021437358A1 (enExample)
BR (1) BR112023019795A2 (enExample)
CA (1) CA3213156A1 (enExample)
CL (1) CL2023002871A1 (enExample)
MX (1) MX2023011546A (enExample)
WO (1) WO2022208146A1 (enExample)
ZA (1) ZA202308388B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PT1919450E (pt) 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
SG170044A1 (en) * 2006-03-31 2011-04-29 Vistakon Pharmaceuticals Llc Ocular allergy treatments
BR112013034055A2 (pt) * 2011-06-29 2017-02-07 Allergan Inc alcaftadina para uso no tratamento de urticária
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
JP7191022B2 (ja) * 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
AU2021291684A1 (en) * 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Also Published As

Publication number Publication date
US20240173331A1 (en) 2024-05-30
KR20230163413A (ko) 2023-11-30
ZA202308388B (en) 2025-11-26
EP4312973A1 (en) 2024-02-07
US20250064825A1 (en) 2025-02-27
US20250064827A1 (en) 2025-02-27
CA3213156A1 (en) 2022-10-06
US12274702B2 (en) 2025-04-15
CN117120029A (zh) 2023-11-24
US20250064826A1 (en) 2025-02-27
CL2023002871A1 (es) 2024-01-26
JP2024512121A (ja) 2024-03-18
MX2023011546A (es) 2023-10-06
WO2022208146A1 (en) 2022-10-06
US20250064828A1 (en) 2025-02-27
US20260007682A1 (en) 2026-01-08
BR112023019795A2 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
US12274702B2 (en) Nasal compositions comprising alcaftadine
US6740660B2 (en) Nasal delivery of apomorphine
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
CN101361725B (zh) 一种含酚妥拉明的外用制剂及其制备方法
EP2736491A2 (en) Bepotastine compositions
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
US20040101484A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
CN120884540A (zh) 一种鼻用制剂及其应用
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
US20230143212A1 (en) Pharmaceutical Preparations Of Melatonin Suitable For Intranasal Administration
RU2818073C2 (ru) Фармацевтическая композиция n,n'-бис[2-(1н-имидазол-4-ил)этил]малонамида
WO2022035388A1 (en) Pharmaceutical compositions comprising azelastine and relevant excipients
CN1389206A (zh) 一种抗白内障眼药和角膜渗透促进剂氮酮的眼科应用